Bolt Biotherapeutics, Inc. (BOLT)
NASDAQ: BOLT · Real-Time Price · USD
4.840
-0.120 (-2.42%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Bolt Biotherapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | 7.7 | 7.69 | 7.88 | 5.73 | 1.26 | |
| Revenue Growth (YoY) | 0.07% | -2.36% | 37.48% | 354.68% | 445.46% | |
| Cost of Revenue | 28.53 | 57.47 | 61.54 | 73.12 | 75.66 | |
| Gross Profit | -20.84 | -49.78 | -53.67 | -67.39 | -74.4 | |
| Selling, General & Admin | 13.8 | 18.46 | 22.53 | 22.93 | 18.39 | |
| Operating Expenses | 13.8 | 18.46 | 22.53 | 22.93 | 18.39 | |
| Operating Income | -34.63 | -68.24 | -76.2 | -90.32 | -92.79 | |
| Interest & Investment Income | 2.5 | 5.26 | 7 | 2.22 | 0.28 | |
| Other Non Operating Income (Expenses) | 0.24 | - | - | - | -6.08 | |
| EBT Excluding Unusual Items | -31.9 | -62.98 | -69.2 | -88.1 | -98.59 | |
| Merger & Restructuring Charges | -1.48 | -3.34 | - | - | - | |
| Asset Writedown | - | -1.47 | - | - | - | |
| Other Unusual Items | - | 4.68 | - | - | - | |
| Pretax Income | -33.38 | -63.12 | -69.2 | -88.1 | -98.59 | |
| Net Income | -33.38 | -63.12 | -69.2 | -88.1 | -98.59 | |
| Net Income to Common | -33.38 | -63.12 | -69.2 | -88.1 | -98.59 | |
| Shares Outstanding (Basic) | 2 | 2 | 2 | 2 | 2 | |
| Shares Outstanding (Diluted) | 2 | 2 | 2 | 2 | 2 | |
| Shares Change (YoY) | -2.06% | 0.98% | 1.21% | 12.54% | 1479.05% | |
| EPS (Basic) | -17.85 | -33.06 | -36.60 | -47.16 | -59.40 | |
| EPS (Diluted) | -17.85 | -33.06 | -36.60 | -47.16 | -59.40 | |
| Free Cash Flow | -39.92 | -61.33 | -69.73 | -78.46 | -59.4 | |
| Free Cash Flow Per Share | -21.35 | -32.12 | -36.88 | -42.00 | -35.79 | |
| Gross Margin | -270.80% | - | - | - | - | |
| Operating Margin | -450.07% | -887.33% | -967.45% | -1576.56% | -7364.13% | |
| Profit Margin | -433.74% | -820.78% | -878.58% | -1537.75% | -7824.68% | |
| Free Cash Flow Margin | -518.80% | -797.53% | -885.36% | -1369.47% | -4714.60% | |
| EBITDA | -33.34 | -66.46 | -74.34 | -88.66 | -91.6 | |
| D&A For EBITDA | 1.29 | 1.78 | 1.85 | 1.67 | 1.19 | |
| EBIT | -34.63 | -68.24 | -76.2 | -90.32 | -92.79 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.